Hemostasis and thrombosis (39)
All Items
-
Hormones and thrombosis: the dark side of the moon: Hormonal therapy and thrombosis
-
Rituximab in the treatment of immune-mediated thrombotic thrombocytopenic purpura: Rituximab in TTP
-
Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding: Emicizumab in acquired hemophilia A
-
Flow-chamber device (T-TAS) to diagnose patients suspected of platelet function defects: Flow-chamber compared with platelet aggregometry
-
Bioequivalence of recombinant factor VIII products: a position paper from the Italian Association of Hemophilia Centers: Bioequivalence of rFVIII concentrates
-
Viscoelastic coagulation testing in Neonatal Intensive Care Units: advantages and pitfalls in clinical practice: Viscoelastic coagulation testing in NICU
-
A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinical practice. The Italian FXIII Study: Clinical and pharmacokinetics features of rFXIII in FXIII deficiency
-
Thrombosis and bleeding after COVID-19 vaccination: do differences in sex matter? COVID-19 vaccine-associated thrombosis and bleeding by sex/gender
-
The effect of exosomes released from apheresis platelet concentrates under the impact of gamma irradiation and storage time upon platelet aggregation and hemostasis: The effect of exosomes isolated from aPCs on haemostasis
-
Validation of PLASMIC score in a cohort of patients with suspected thrombotic microangiopathy in an academic medical centre: Validation of PLASMIC score
-
Heparin-induced thrombocytopenia: effect of heat inactivation of patient’s serum on functional flow cytometric assay results: HIT: heat inactivation of serum in a FC assay
-
Transfusion of fibrinogen concentrate before dental extractions in patients with afibrinogenemia: a narrative review supported by a case report with a proposed treatment protocol: Oral health in afibrinogenemia
-
Efficacy and safety of von Willebrand factor concentrate almost devoid of factor VIII (Wilfactin®) in paediatric patients under 6 years of age with severe von Willebrand disease: Wilfactin® in VWD patients under 6 years of age
-
Acquired von Willebrand syndrome in patients with monoclonal gammopathy of undetermined significance investigated using a mechanistic approach
39 Items
Announcements
Winter Closure
The Editorial Office will be closed from December 31 to January 7, 2026.
Season’s greetings to all our readers, authors, and reviewers.
Read moreSIMTI 2026
46° Convegno Nazionale di Studi di Medicina Trasfusionale - Abstract Book (in Italian)
Read moreSETS 2026
35° Congreso de la Sociedad Española de Transfusión Sanguínea y Terapia Celular - SETS - Abstract Book (in Spanish), is online (https://www.bloodtransfusion.it/bt/issue/view/81).Madrid, 4-6 June 2026.
Read moreEditorial Office Closure Notice
Please note that the BT Editorial Office will be closed until August 26, 2026.
During this period, responses to inquiries and the processing of manuscripts may be delayed. All editorial activities will resume as usual after this date.
Thank you for your understanding.
Best regards,
BT Editorial Office
Read more
Impact Factor 2025
We are pleased to announce that Blood Transfusion has achieved a 2025 Impact Factor of 2.7.
Read more